Drug · Small Molecule

Cisplatin

CI-DRUG-00000157Explore in graph →NCIt C376 CHEMBL11359 CIViC Approved

Regulatory

Approvals (16)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory16 approval records from 2 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION BP (DIN 02536285) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Feb 23, 2024	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION (DIN 02403188) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Aug 29, 2013	health-canada-dpd
CA Health Canada	—	Marketed in Canada as CISPLATIN INJECTION, MYLAN STD. (DIN 02396890) under ATC L01XA01 CISPLATIN. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	withdrawnsource: Cancelled Post Marketsince Jul 6, 2016

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 18 hours agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	604	294	672	2,478	16	CA, US	Dec 19, 1978	1988-04
Malignant Bladder Neoplasm	Approved	Phase 3	27	10	17	93	1	US	Dec 19, 1978	1995-05
Malignant Lung Neoplasm	Phase4	Phase 4	143	58	173	556	0	—	—	1993-01
Malignant Cervical Neoplasm	Phase4	Phase 4	38	18	51	160	0

Curated evidence

Clinical evidence (78)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–50 of 78 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
CD80 Overexpression1
Cisplatin + Galiximab

Clinical trials

Trials with this intervention (2,504)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–50 of 2,504 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03418038	Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia	recruiting	Phase 2	80	Mayo ClinicOTHER	1	Sep 28, 2026	clinicaltrials
NCT03976323	Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: Q20Q21Q62J
Aliases: Abiplatin, Blastolem, Briplatin, CDDP, CIS-DDP, Cis-diamminedichloridoplatinum, Cis-diammine-dichloroplatinum, Cis-diamminedichloroplatinum, Cis-diamminedichloroplatinum(ii), Cis-diamminedichloro Platinum (II), Cis-dichloroammine Platinum (II), Cismaplat, Cis-platin, Cisplatin, Cisplatina, CISPLATIN COMPONENT OF INT-230-6, CISPLATIN COMPONENT OF INT230-6, Cisplatine, CISPLATIN INJECTION, MYLAN STD., Cisplatino, Cis-platinous Diamine Dichloride, Cis-platinum, Cisplatinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP … (+27)

Data updated 21 hours agoSource updated unknown

Identifiers

Codes (27)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01XA01	CISPLATIN
DIN (Health Canada)	00644293

ERCC1 Expression2
Cisplatin	Bladder Carcinoma	Predictive	B	Does Not Support Sensitivity Response	4	accepted	EID809 Immunhistochemistry of ERCC1 expression in 432 patients revealed no correlation to response to cisplatin based chemotherapy. In-vitro studies also did not show any effects. PMID 26162296 · Klatte et al., 2015 · Open in CIViC	civic
Cisplatin + Gemcitabine + PaclitaxelCombination	Bladder Carcinoma	Predictive	B	Supports N/A	3	submitted	EID6438 With a cut-off of seven, 37 patients were classified as having low ERCC1 expression and 20 as having high ERCC1 expression. OS was significantly longer for patients with low ERCC1 levels (25.47 months… (full text at CIViC) PMID 17229776 · Bellmunt et al., 2007 · Open in CIViC	civic

PIK3CA E545K3
Cisplatin + PictilisibCombination	Cervical CarcinomaALIAS	Predictive	D	Supports Sensitivity Response	3	accepted	EID2984 CaSki cells that are heterozygous for the PIK3CA-E545K mutation are more resistant to cisplatin or cisplatin plus radiation than either HeLa or SiHa cells that express only wild-type PIK3CA. Similarly… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC	civic
Cisplatin	Malignant Cervical Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID2985 Authors tested various cervical cancer cell lines (CaSki, SiHa and HeLa) for their responses to cisplatin, radiation therapy, and GDC-0941. CaSki cells that are heterozygous for the PIK3CA-E545K mutat… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC	civic
Cisplatin + Ionizing RadiotherapySequential	Malignant Cervical Neoplasm	Predictive	D	Supports Resistance	3	accepted	EID8112 Cervical cancer cell lines were treated with 1uM cisplatin followed by 1-6Gy ionizing radiation (IR). CaSki cells with PIK3CA E545K mutation show resistance to cisplatin plus IR when compared with HeL… (full text at CIViC) PMID 27489350 · Arjumand et al., 2016 · Open in CIViC	civic

AURKA Overexpression2
Alisertib + CisplatinCombination	Esophageal AdenocarcinomaALIAS	Predictive	D	Supports Sensitivity Response	4	submitted	EID9627 The efficacy of novel AURKA inhibitor alisertib (MLN8327) was tested alone or in combination with cisplatin in three esophageal adenocarcinoma cell lines (FLO-1, OE19 and OE33) that overexpress AURKA.… (full text at CIViC) PMID 22302096 · Sehdev et al., 2012 · Open in CIViC	civic
Cisplatin	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Resistance	4	accepted	EID871 High levels of Aurora-A expression (retrospectively assessed by IHC in 102 NSCLC patients) predicted poorer overall survival and progression free survival in a population treated with surgery and cisp… (full text at CIViC) PMID 25082261 · Xu et al., 2014 · Open in CIViC	civic

ACTL6A Overexpression2
Cisplatin	Lung Adenocarcinoma	Predictive	D	Supports Resistance	4	submitted	EID8977 High expression of ACTL6A has been shown to be associated with resistance to cisplatin in multiple cancer types. In vitro experiments using A549 and H1299 lung cancer cell lines showed that overexpres… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC	civic
Cisplatin + PanobinostatCombination	Lung Adenocarcinoma	Predictive	D	Supports Sensitivity Response	4	submitted	EID8978 ACTL6A plays a role in DNA damage repair by maintaining integrity of the SWI/SNF complex, and is associated with resistance to cisplatin. Results from cell viability and survival assays showed that tr… (full text at CIViC) PMID 33408251 · Xiao et al., 2021 · Open in CIViC	civic

ERCC1 Underexpression2
Cisplatin	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	submitted	EID6433 In this review article, the median survival of non-small cell lung cancer patients with low levels of ERCC1, treated with platinum-based therapies was significantly prolonged as compared to those with… (full text at CIViC) PMID 16807441 · Rosell et al., 2006 · Open in CIViC	civic
Cisplatin + GemcitabineCombination	Lung Non-Small Cell CarcinomaCURATED_BROADER	Predictive	B	Supports Sensitivity Response	4	submitted	EID6431 The Median Survival Time (MST) in patients with low ERCC1 mRNA levels was significantly longer in the overall population than in patients with higher ERCC1 levels (17.3 versus 10.9 months, log-rank 8.… (full text at CIViC) PMID 16980606 · Ceppi et al., 2006 · Open in CIViC	civic